RIA
OTLKW

Realta Investment Advisors’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Realta Investment Advisors’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed – – 1543
2019
Q4 		$0 Hold
500
– – ﹤0.01% 1718
2019
Q3 		$0 Hold
500
– – ﹤0.01% 1858
2019
Q2 		$0 Hold
500
– – ﹤0.01% 1847
2019
Q1 		$0 Buy
+500
New +$160 ﹤0.01% 1363

Other funds holding OTLKW

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
CIA
Compass Ion Advisors Conshohocken, Pennsylvania $1.05B AUM 16.28% 1-Year Est. Return

Realta Investment Advisors's OTLKW Position: Q1 2020 in Review

Realta Investment Advisors sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q1 2020, closing a stake of 500 shares.

Realta Investment Advisors first reported a position in OTLKW in Q1 2019 and held it in 4 quarters. The position peaked at $0 in Q4 2019. 6 funds tracked by Wall St. Rank hold OTLKW as of Q1 2020.

  • Realta Investment Advisors reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q1 2020 after selling out during the quarter.
  • Realta Investment Advisors sold 500 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q1 2020.
  • Realta Investment Advisors first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q1 2019 and held it in 4 quarters.
  • Realta Investment Advisors's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $0 in Q4 2019.
  • 6 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.